Fig. 4From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid CancerSecreted VEGFC expression and tube formation assay in conditioned media of indicated GSP2 and GSP3. a and b SoLAT suppressed VEGF secretion compared to that in the no treatment or single treatment group. c VEGF-induced tube formation assay of HUVECs showed that the tube length decreased in the SoLAT groupBack to article page